NEW YORK (GenomeWeb News) — SensiGen today said it will use Sequenom’s MassArray platform and QGE gene-expression tools to continue to develop several disease assays that the companies will co-market to reference labs for an indefinite period.
The first of SensiGen’s AttoSense tests to be developed on the Sequenom platform will be an assay for human papillomavirus. The company plans to submit that test to the US Food and Drug Administration by 2009.
SensiGen plans to develop three other tests, including assays for chronic kidney disease, inflammatory bowel disease, and lupus.
The companies said the AttoSense assay method can detect DNA from viruses, bacteria, blood, urine, and tissue.
Financial terms of the agreement were not released.